Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)

Next Previous
X
Search
Trial Profile

Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Teropavimab (Primary) ; Zinlirvimab (Primary) ; Antibodies
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms BEAT-2; BEAT-HIV-02

    • Most Recent Events

    • 06 Mar 2024 Results (n=8) assessing relative selective pressure of bnAbs and anAbs in the BEAT2 study of 3BNC117, 10-1074, and IFNa2b, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
    • 06 Mar 2024 Results reporting a novel VL test based on capillary blood collection, comparing its specificity and sensitivity to conventional clinic-based plasma-based VL (pVL) presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 06 Mar 2024 Results evaluating the effect of a 26-week immunotherapy course with peg-IFN-alpha2b+bNAbs in the cytotoxic function and activation of natural killer (NK) cell subsets in persons with HIV infection (PWH) that participated in the BEAT 2 study presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top